Imbalance of the C4A and C4B genes dosage as a robust risk factor for premature cardiovascular disease morbidity and mortality

2007 ◽  
Vol 44 (1-3) ◽  
pp. 173
Author(s):  
George Füst ◽  
Mária Sasvári ◽  
Bernadett Blaskó ◽  
Csaba Szalai ◽  
Róza Ádány ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Risk Factor ◽  
Morbidity And Mortality ◽  
Premature Cardiovascular Disease

scholarly journals RISK FACTOR ASSESSMENT FOR THE PREVENTION OF PREMATURE CARDIOVASCULAR DISEASE IN CLINICAL PRACTICE

2013 ◽  
Vol 61 (10) ◽  
pp. E1432
Author(s):  
Julian P. Halcox ◽  
Nicholas D. Gollop ◽  
Arron S. Lacey ◽  
William H. King
Keyword(s):  
Cardiovascular Disease ◽  
Risk Factor ◽  
Clinical Practice ◽  
Risk Factor Assessment ◽  
Premature Cardiovascular Disease

Hyperlipidemia Screening Is Worthwhile

PEDIATRICS ◽  
1980 ◽  
Vol 65 (3) ◽  
pp. 674-674
Author(s):  
Peter C. Freis
Keyword(s):  
Risk Factors ◽  
Cardiovascular Disease ◽  
Risk Factor ◽  
Family History ◽  
Pediatric Patients ◽  
Coronary Risk Factors ◽  
Coronary Risk ◽  
Primary Physician ◽  
Premature Cardiovascular Disease ◽  
History Of

Neil A. Holtzman, MD (Hyperlipidemia screening: A search for heffalumps. Pediatrics 64:270, 1979) writes persuasively discouraging hypercholesterolemia screening and therapy in childhood. His commentary would easily dissuade the primary physician from appropriate intervention on his pediatric patients' behalf to minimize every coronary risk factor. The author unfortunately pays little attention to the children who would benefit most from hypercholesterol screening, those with a family history of premature cardiovascular disease. This is misleading. We must redirect our thinking to a continued effort to seek and minimize more appropriately coronary risk factors.

The Pharmacokinetics of Bezafibrate in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis (CAPD)

1986 ◽  
Vol 6 (2) ◽  
pp. 69-71 ◽  
Author(s):  
Anthony J. Williams ◽  
John Walls
Keyword(s):  
Cardiovascular Disease ◽  
Risk Factor ◽  
Normal Population ◽  
Significant Proportion ◽  
Elevated Serum ◽  
Serum Triglyceride ◽  
Normal Subjects ◽  
Morbidity And Mortality ◽  
Pharmacokinetic Properties ◽  
Hypolipidemic Agent

Patients on CAPD often have hyperlipidemia -a known risk factor for morbidity and mortality from cardiovascular disease. We have defined the pharmacokinetic properties of bezafibrate, a new hypolipidemic agent, in CAPD patients. Its serum half-life was prolonged approximately 10 times that of normal subjects, and less than 2% of an oral 200 mg dose appears in the dialysate after 48 hours. If indicated, an appropriate dose for the treatment of hyperlipidemia in the CAPD population would be 200 mg bezafibrate every third day. Cardiovascular disease remains one of the main causes of morbidity and mortality among patients with end stage renal disease (I). Hyperlipidemia, a known risk factor in the normal population, may be involved in the progression of arterial disease in such patients (2). The hyperlipidemia associated with CAPD is related to the absorption of large quantities of glucose during dialysis (3), and attempts to treat the hyperlipidemia by low-dose intraperitoneal insulin (4) and dietary carbohydrate restriction (3), have met with only limited success. Bezafibrate, a new hypolipidemic agent, is effective in reducing elevated serum triglyceride and cholesterol levels in various hyperlipidemic conditions (5). However, because its pharmacokinetic properties are altered in patients with renal impairment (6), it is necessary to adjust the dose to compensate for the significant proportion of the drug that is excreted in the urine. This study was done to define the pharmacokinetics of bezafibrate in patients receiving CAPD in order to establish a safe dosage.

B-Vitamins, Methylenetetrahydrofolate Reductase (MTHFR) and Hypertension

2011 ◽  
Vol 81 (4) ◽  
pp. 240-244 ◽  
Author(s):  
Mary Ward ◽  
Carol P Wilson ◽  
J J Strain ◽  
Geraldine Horigan ◽  
John M. Scott ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Cardiovascular Disease ◽  
Risk Factor ◽  
Low Dose ◽  
Methylenetetrahydrofolate Reductase ◽  
Genetic Determinant ◽  
Gene Encoding ◽  
Homocysteine Concentration ◽  
Homozygous Mutant ◽  
B Vitamin

Hypertension is a leading risk factor for cardiovascular disease (CVD) and stroke. A common polymorphism in the gene encoding the enzyme methylenetetrahydrofolate reductase (MTHFR), previously identified as the main genetic determinant of elevated homocysteine concentration and also recognized as a risk factor for CVD, appears to be independently associated with hypertension. The B-vitamin riboflavin is required as a cofactor by MTHFR and recent evidence suggests it may have a role in modulating blood pressure, specifically in those with the homozygous mutant MTHFR 677 TT genotype. If studies confirm that this genetic predisposition to hypertension is correctable by low-dose riboflavin, the findings could have important implications for the management of hypertension given that the frequency of this polymorphism ranges from 3 to 32 % worldwide.

Sign in / Sign up

Export Citation Format

Share Document